September 2, 2021Purinergic Signalling50 citationsOpen Access

Recommended tool compounds and drugs for blocking P2X and P2Y receptors

CMChrista E. Müller VNVigneshwaran Namasivayam

Key Points

Key points are not available for this paper at this time.

Abstract

This review article presents a collection of tool compounds that selectively block and are recommended for studying P2Y and P2X receptor subtypes, investigating their roles in physiology and validating them as future drug targets. Moreover, drug candidates and approved drugs for P2 receptors will be discussed.

KI fragen

Bookmark

View Full Paper

Cite This Study

Müller et al. (2021) studied this question.

synapsesocial.com/papers/69d80c9066a29169b4bede50 https://doi.org/https://doi.org/10.1007/s11302-021-09813-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors2004 · 167 citations
2NF546 [4,4′-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-α,α′-diphosphonic Acid) Tetrasodium Salt] Is a Non-Nucleotide P2Y11 Agonist and Stimulates Release of Interleukin-8 from Human Monocyte-Derived Dendritic Cells2009 · 93 citations
3Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough2020 · 9 citations
4Ectonucleoside triphosphate diphosphohydrolases and ecto-5′-nucleotidase in purinergic signaling: how the field developed and where we are now2020 · 70 citations
5Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants2018 · 65 citations

KI fragen

Bookmark

View Full Paper